461 related articles for article (PubMed ID: 8878282)
21. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies.
Rice JD; McIntosh SF; Halstead AC
Prenat Diagn; 2005 Mar; 25(3):234-8. PubMed ID: 15791658
[TBL] [Abstract][Full Text] [Related]
22. Second-trimester maternal serum analyte levels associated with fetal trisomy 13.
Saller DN; Canick JA; Blitzer MG; Palomaki GE; Schwartz S; Blakemore KJ; Haddow JE
Prenat Diagn; 1999 Sep; 19(9):813-6. PubMed ID: 10521837
[TBL] [Abstract][Full Text] [Related]
23. Elevated maternal mid-trimester chorionic gonadotropin > or =4 MoM is associated with fetal cerebral blood flow redistribution.
Hershkovitz R; Erez O; Sheiner E; Landau D; Mankuta D; Mazor M
Acta Obstet Gynecol Scand; 2003 Jan; 82(1):22-7. PubMed ID: 12580835
[TBL] [Abstract][Full Text] [Related]
24. Early detection of preeclampsia using inhibin a and other second-trimester serum markers.
Ree PH; Hahn WB; Chang SW; Jung SH; Kang JH; Cha DH; Kang MS; Huh JY
Fetal Diagn Ther; 2011; 29(4):280-6. PubMed ID: 21252475
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
MacDonald ML; Wagner RM; Slotnick RN
Obstet Gynecol; 1991 Jan; 77(1):63-8. PubMed ID: 1701526
[TBL] [Abstract][Full Text] [Related]
26. Cystic hygroma and mid-trimester maternal serum screening.
Celentano C; Prefumo F; Iezzi I; Guanciali-Franchi PE; Palka C; Liberati M; Rotmensch S
J Med Screen; 2007; 14(3):109-12. PubMed ID: 17925081
[TBL] [Abstract][Full Text] [Related]
27. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
28. Elevated maternal serum alpha-fetoprotein and amniotic fluid alpha-fetoprotein after multifetal pregnancy reduction.
Grau P; Robinson L; Tabsh K; Crandall BF
Obstet Gynecol; 1990 Dec; 76(6):1042-5. PubMed ID: 1700349
[TBL] [Abstract][Full Text] [Related]
29. Lack of correlation between elevated maternal serum hCG during second-trimester biochemical screening and fetal congenital anomaly.
Celentano C; Guanciali-Franchi PE; Liberati M; Palka C; Fantasia D; Morizio E; Calabrese G; Stuppia L; Rotmensch S
Prenat Diagn; 2005 Mar; 25(3):220-4. PubMed ID: 15791663
[TBL] [Abstract][Full Text] [Related]
30. Second-trimester maternal serum alpha-fetoprotein elevation and its association with adverse maternal/fetal outcome: ten years experience.
Anfuso S; Soncini E; Bonelli P; Piantelli G; Gramellini D
Acta Biomed; 2007 Dec; 78(3):214-9. PubMed ID: 18330082
[TBL] [Abstract][Full Text] [Related]
31. Quad screen as a predictor of adverse pregnancy outcome.
Dugoff L; Hobbins JC; Malone FD; Vidaver J; Sullivan L; Canick JA; Lambert-Messerlian GM; Porter TF; Luthy DA; Comstock CH; Saade G; Eddleman K; Merkatz IR; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2005 Aug; 106(2):260-7. PubMed ID: 16055573
[TBL] [Abstract][Full Text] [Related]
32. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?
Sancken U; Bartels I
Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279
[TBL] [Abstract][Full Text] [Related]
33. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption.
Tikkanen M; Hämäläinen E; Nuutila M; Paavonen J; Ylikorkala O; Hiilesmaa V
Prenat Diagn; 2007 Mar; 27(3):240-3. PubMed ID: 17238224
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the thresholds of abnormal second trimester multiple marker screening tests associated with intra-uterine growth restriction.
Odibo AO; Sehdev HM; Stamilio DM; Macones GA
Am J Perinatol; 2006 Aug; 23(6):363-7. PubMed ID: 16841275
[TBL] [Abstract][Full Text] [Related]
35. Re: Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction.
Shulman LP; Phillips OP
Prenat Diagn; 1997 May; 17(5):488-90. PubMed ID: 9178329
[No Abstract] [Full Text] [Related]
36. [Significance of the maternal levels of serum alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol in various congenital developmental defects in pregnancy trimester II].
Kostiuk EV; Zolotukhina TV; Kuznetsov MI
Genetika; 1992 Sep; 28(9):158-62. PubMed ID: 1282117
[TBL] [Abstract][Full Text] [Related]
37. Altered newborn gender distribution in patients with low mid-trimester maternal serum human chorionic gonadotropin (MShCG).
Santolaya-Forgas J; Meyer WJ; Burton BK; Scommegna A
J Matern Fetal Med; 1997; 6(2):111-4. PubMed ID: 9086428
[TBL] [Abstract][Full Text] [Related]
38. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus.
Huttly W; Rudnicka A; Wald NJ
Prenat Diagn; 2004 Oct; 24(10):804-7. PubMed ID: 15503275
[TBL] [Abstract][Full Text] [Related]
39. Maternal serum analyte levels after first-trimester multifetal pregnancy reduction.
Shulman LP; Phillips OP; Cervetti TA
Am J Obstet Gynecol; 1996 Mar; 174(3):1072-4. PubMed ID: 8633639
[TBL] [Abstract][Full Text] [Related]
40. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies.
Jauniaux E; Gulbis B; Tunkel S; Ramsay B; Campbell S; Meuris S
Prenat Diagn; 1996 Dec; 16(12):1129-35. PubMed ID: 8994249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
